Results 131 to 140 of about 482,588 (310)

Left ventricular hypertrophy in athletes and hypertensive patients

open access: yesThe Journal of Clinical Hypertension, 2017
D. Lovic   +5 more
semanticscholar   +1 more source

The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Proposed algorithm to screen for transthyretin cardiac amyloidosis (ATTR‐CA). AL‐CA, immunoglobulin light‐chain cardiac amyloidosis; AMYLI, AMYLoidosis Index; AUC, area under the curve; IWT, increased wall thickness; LVEF, left ventricular ejection fraction; PYP, pyrophosphate.
Giovanni Battista Bonfioli   +11 more
wiley   +1 more source

GENETICS OF LEFT VENTRICULAR HYPERTROPHY

open access: yes, 2012
High blood pressure makes the heart work harder and promotes enlargement of the left ventricle, left ventricular hypertrophy (LVH), which is an important risk factor for cardiovascular disease and death. LVH is characterized for the most part by two different sets of observable characteristics (genetic phenotypes): an enlarged left ventricle (1) due to
openaire   +2 more sources

Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease.

open access: yesAmerican Journal of Kidney Diseases, 2016
P. McCullough   +4 more
semanticscholar   +1 more source

Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.

open access: yesAmerican Society of Nephrology. Clinical Journal, 2016
E. Paoletti   +12 more
semanticscholar   +1 more source

Computational modelling of myocardial metabolism in patients with advanced heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction. Abstract Aims Perturbations of myocardial metabolism and energy depletion are well‐established hallmarks of heart failure (HF), yet methods for their systematic assessment remain limited in humans.
Niklas Beyhoff   +17 more
wiley   +1 more source

Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides

open access: yesEuropean Journal of Heart Failure, EarlyView.
Cancer patients presenting to the emergency department ED with dyspnoea. Among 2153 patients presenting to the ED with dyspnea, 473 (22.0%) had an active or past cancer. Acute heart failure (AHF) was the most common final diagnosis in both groups. Pneumonia and cancer‐related dyspnoea were more common in cancer patients.
Paolo Bima   +20 more
wiley   +1 more source

Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure – interaction between loss of Y chromosome and clonal haematopoiesis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Age‐associated clonal haematopoiesis of indeterminate potential (CHIP) has been linked to increased incidence and worse prognosis of chronic heart failure (CHF). CHIP arises from somatic mutations in haematopoietic stem and progenitor cells. Mosaic loss of Y chromosome (LOY), the most common somatic mutation in male blood cells, increases
Sebastian Cremer   +15 more
wiley   +1 more source

Electrocardiographic Criteria for the Diagnosis of Left Ventricular Hypertrophy.

open access: yesJournal of the American College of Cardiology, 2017
J. Peguero   +5 more
semanticscholar   +1 more source

Clustering in dilated cardiomyopathy at initial evaluation: An effective tool for clinical stratification

open access: yesEuropean Journal of Heart Failure, EarlyView.
Visual description of study design and main results. BBB, bundle branch block; ECG, electrocardiogram; MVA, major ventricular arrhythmia; SCD, sudden cardiac death. Abstract Aims Dilated cardiomyopathy (DCM) has a highly variable presentation and disease course. Current stratification strategies are complex and require multimodality evaluation.
Ilaria Gandin   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy